Virus like particle-based vaccines against emerging infectious disease viruses

Liu, Jinliang; Dai, Shiyu; Wang, Manli; Hu, Zhihong; Wang, Hualin; Dèng, Fēi

doi:10.1007/s12250-016-3756-y

Cited by 42 publications

(42 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A variety of nanoparticles including VLPs are being developed for biomedical applications [41] , [42] , [43] , [44] , [45] , [46] . However, information regarding their biological behaviours in vivo is still limited.…”

Section: Discussionmentioning

confidence: 99%

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

et al. 2017

View full text Add to dashboard Cite

Hepatitis B Virus core (HBc) particles have been studied for their potential as drug delivery vehicles for cancer therapy. HBc particles are hollow nano-particles of 30–34 nm diameter and 7 nm thick envelopes, consisting of 180–240 units of 21 kDa core monomers. They have the capacity to assemble/dis-assemble in a controlled manner allowing encapsulation of various drugs and other biomolecules. Moreover, other functional motifs, i.e. receptors, receptor binding sequences, peptides and proteins can be expressed. This study focuses on the development of genetically modified HBc particles to specifically recognise and target human epidermal growth factor receptor-2 (HER2)-expressing cancer cells, in vitro and in vivo, for future cancer therapy. The non-specific binding capacity of wild type HBc particles was reduced by genetic deletion of the sequence encoding arginine-rich domains. A specific HER2-targeting was achieved by expressing the ZHER2 affibodies on the HBc particles surface. In vitro studies showed specific uptake of ZHER2-ΔHBc particles in HER2 expressing cancer cells. In vivo studies confirmed positive uptake of ZHER2-ΔHBc particles in HER2-expressing tumours, compared to non-targeted ΔHBc particles in intraperitoneal tumour-bearing mice models. The present results highlight the potential of these nanocarriers in targeting HER2-positive metastatic abdominal cancer following intra-peritoneal administration.

show abstract

Section: Discussionmentioning

confidence: 99%

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although these molecular structures resemble whole virus particles, they do not have genetic material and are therefore unable to infect cells and self-replicate, making them a very safe choice for vaccine formulations [24]. Additionally, VLPs are known for their efficiency at presenting heterologous target antigens-a strategy that can radically alter the magnitude of the immune response, thereby significantly improving the protection that the new vaccines confer [25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

et al. 2020

View full text Add to dashboard Cite

Plasmodium vivax is the most common species of human malaria parasite found outside Africa, with high endemicity in Asia, Central and South America, and Oceania. Although Plasmodium falciparum causes the majority of deaths, P. vivax can lead to severe malaria and result in significant morbidity and mortality. The development of a protective vaccine will be a major step toward malaria elimination. Recently, a formulation containing the three allelic variants of the P. vivax circumsporozoite protein (PvCSP—All epitopes) showed partial protection in mice after a challenge with the hybrid Plasmodium berghei (Pb) sporozoite, in which the PbCSP central repeats were replaced by the VK210 PvCSP repeats (Pb/Pv sporozoite). In the present study, the chimeric PvCSP allelic variants (VK210, VK247, and P. vivax-like) were fused with the mumps virus nucleocapsid protein in the absence (NLP-CSPR) or presence of the conserved C-terminal (CT) domain of PvCSP (NLP-CSPCT). To elicit stronger humoral and cellular responses, Pichia pastoris yeast was used to assemble them as nucleocapsid-like particles (NLPs). Mice were immunized with each recombinant protein adjuvanted with Poly (I:C) and presented a high frequency of antigen-specific antibody-secreting cells (ASCs) on days 5 and 30, respectively, in the spleen and bone marrow. Moreover, high IgG titers against all PvCSP variants were detected in the sera. Later, these immunized mice with NLP-CSPCT were challenged with Pb/Pv sporozoites. Sterile protection was observed in 30% of the challenged mice. Therefore, this vaccine formulation use has the potential to be a good candidate for the development of a universal vaccine against P. vivax malaria.

show abstract

“…The antigens are present in their native conformation (without involving a replicating virus). VLPs can serve as excellent platforms for the development of efficient vaccines, since they have the ability to induce strong humoral and cellular responses, allow rapid testing of multiple candidate antigen designs and are associated with a safer manufacturing process (Liu et al 2016 ). Studies of ZIKV (Boigard et al 2017 ; Yang et al 2017 ; Garg et al 2017 ) and other flaviviruses, such as tick-borne encephalitis virus (TBEV) (Allison et al 1995 ), dengue fever virus (DENV) (Shang et al 2012 ) and Japanese encephalitis virus (JEV) (Du et al 2015 ), have showed that expression of the structural proteins prM and E is sufficient for the assembly and release of VLPs that are morphologically and antigenically similar to the native virions.…”

Section: Introductionmentioning

confidence: 99%

Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice

Dai

Zhang

et al. 2018

Virol. Sin.

Self Cite

View full text Add to dashboard Cite

The newly emerged mosquito-borne Zika virus (ZIKV) strains pose a global challenge owing to its ability to cause microcephaly and neurological disorders. Several ZIKV vaccine candidates have been proposed, including inactivated and live attenuated virus vaccines, vector-based vaccines, DNA and RNA vaccines. These have been shown to be efficacious in preclinical studies in mice and nonhuman primates, but their use will potentially be a threat to immunocompromised individuals and pregnant women. Virus-like particles (VLPs) are empty particles composed merely of viral proteins, which can serve as a safe and valuable tool for clinical prevention and treatment strategies. In this study, we used a new strategy to produce ZIKV VLPs based on the baculovirus expression system and demonstrated the feasibility of their use as a vaccine candidate. The pre-membrane (prM) and envelope (E) proteins were co-expressed in insect cells and self-assembled into particles similar to ZIKV. We found that the ZIKV VLPs could be quickly and easily prepared in large quantities using this system. The VLPs were shown to have good immunogenicity in immunized mice, as they stimulated high levels of virus neutralizing antibody titers, ZIKV-specific IgG titers and potent memory T cell responses. Thus, the baculovirus-based ZIKV VLP vaccine is a safe, effective and economical vaccine candidate for use against ZIKV.

show abstract

Virus like particle-based vaccines against emerging infectious disease viruses

Cited by 42 publications

References 64 publications

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice

Contact Info

Product

Resources

About